Introduction 52
Over the past decade there has been increased awareness from the public on issues related 53 to farm animal welfare. More specifically, concern over procedures that inflict pain upon pigs (i.e. 54 castration, tail docking) and lack of pain relief available during these procedures has been 55 highlighted as major concerns from the public (Guatteo et al., 2012; Coetzee, 2013a; Millman, 56 2013 ). Non-steroidal anti-inflammatory drugs (NSAIDs) including ketoprofen, carprofen, flunixin 57 meglumine and meloxicam are common analgesics used to manage animal pain and are labeled 58 for pain control for livestock in Canada and some European Union countries (Coetzee, 2013b) . 59
However there are currently no drugs approved for use in swine and specifically labelled to provide 60 pain relief in the United States (FDA 2010) . 61
Meloxicam is a member of the oxicam class with anti-inflammatory, analgesic and antipyretic 62
properties (Friton et al., 2003; Hirsch et al., 2003) . Meloxicam is highly protein bound (95-99%), 63 demonstrates good systemic absorption (Busch et al,. 1998 ) and may be a good candidate for pain 64 mitigation in swine. To identify the optimal dose regimen for pain management, the 65 pharmacokinetics of a drug must be determined. Pharmacokinetic (PK) parameters for meloxicam 2008; 2010). However, these studies evaluated meloxicam PK properties in pre-pubertal swine age 72 14-23 days and neither study evaluated oral bioavailability (F) of meloxicam. The purpose of this 73 study was to compare the pharmacokinetic parameters of IV and oral meloxicam PK in mature 74 swine and to determine the oral bioavailability. 75
Methods 76
This study was approved by the Institutional Animal Care and Use Committee at Iowa 77 State University. 78 standard deviation = 217.3± 65.68 kg) were used for this study. Sows were housed in individual 82 pens with a concrete floor with and rubber mat (2.4 m length x 2 cm height x 1.4 m width). Sows 83 were provided ad libitum access to water via one nipple drinker (Trojan Specialty Products Model 84 65, Dodge City, KS) and hand-fed a custom mixed diet free of antibiotics or medications composed 85 of corn, soybean meal and soy hulls, designed to meet or exceed nutrient requirements for sows. 86 Approximately 1.8 kg of feed was fed at 0800 and 0.45 kg of feed was fed at 1600 hours onto a 87 raised concrete step (55 cm length x 55 cm in width x 24 cm). Matrix (Altrenogest formulation; 88
Intervet/Schering-Plough, Milsboro, DE-Dose: 6.8 ml-15 mg) was added to one kg of feed daily 89 to prevent estrus cycle initiation. 90
Twenty-four hours before study commencement, sows were moved to individual gestation 91 stalls (2.1 m length x 0.6 m width) with nonslip rubber flooring. Sows had access to the same type 92 of nipple drinker previously described for the pen, and remained in their stalls for a total of 72 93 hours while on trial (on trial defined as sows receiving drug and having blood collected). Sows on 94 trial, regardless of administration route, received the same ration and were fed on the same 95 schedule as follows: Day 1: 0.9 kg at 5:00 (three and half hours prior to oral drug administration), 96 1.4 kg at 12:30 and .45 kg at 17:00; Day 2: 2.3 kg at 8:30 and 0.45 kg at 17:00. Lights were on a 97 12:12 light dark cycle (light hours [0600 and 1800]). Feed schedule was different on trial days due 98 to trial schedule and blood collection time-points. Attitude, appetite, and blood collection sites of 99 sows were monitored twice daily during each study period. Sows were assessed for immediate 100 adverse reactions to drug administration including demonstrating signs of sedation, seizures, 101 vomiting, diarrhea or respiratory compromise. Post-mortem necropsies were not conducted and A cross-over design study (Navidi, 2008) was conducted over two rounds such that all 105 sows received each administrative route. Sows were blocked by body weight and treatments were 106 randomly assigned to sows within a block (three sows per block) with three sows allocated to each 107 administration route for the first round. A10-day washout period was chosen as it was greater than 108 89 times the half-life reported in swine (Fosse et al., 2008; T1/2 b : 2.7 hours). Sows were weighed 109 20 hours prior to study initiation and these weights were used to calculate drug dosages. 110
In the first round, three sows were administered an intravenous injection of meloxicam 111 cookie dough (sows had been previously trained using cookie dough as a positive reinforcement), 117 divided into three, 8 gram round balls, and administered in a clean feeding bowl. In the second 118 round, this process was repeated so that all sows received both meloxicam routes. For oral 119 administration, the dose was rounded to the nearest whole tablet. For intravenous administration, 120 the dose was rounded to the nearest half milliliter. The experimental unit was the individual sow 121 (n = 6/treatment). 122
Blood collection 123
All blood samples (9.0 mL/sample) were collected via the jugular vein using a 25.4 mm 16 124 gauge hypodermic needle (Air-Tite Products, Virginia Beach, VA, USA) and 12 ml luer lock 125 syringe (TycoHealth Care, Mansfield, MA, USA). During blood collection, sows were manually 7 restrained using a pig snare. Blood was collected from sows receiving IV-M at 0.05, 0.1, 0.17, 127 0.33, 0.5, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours after drug administration. Blood was collected 128 from sows receiving PO-M at 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, and 48 hours after PO 129 administration. A baseline sample was collected 20 hours prior to drug administration for both 130 routes. Samples were immediately transferred to a sodium heparin 10 ml blood collection tube 131 (BD Vacutainer, Franklin Lakes, NJ, USA) and remained on ice for no longer than 150 minutes 132 prior to centrifugation for 10 minutes at 1,500 g. Collected plasma was placed in cryovials and 133 frozen at -70 °C until analysis. 134
HPLC/MS analysis of meloxicam concentrations 135
Plasma meloxicam concentrations were determined using high-pressure liquid chromatography 136 (Surveyor MS Pump and Autosampler, Thermo Scientific, San Jose, CA, USA) with mass 137 spectrometry (TSQ Quantum Discovery MAX, Thermo Scientific, San Jose, CA, USA). Plasma 138 samples, spikes (0.20 ml) and the internal standard (piroxicam; 10 μL 40ng/ml) were treated with 139 20 μL of 30% perchloric acid. Samples were vortexed for 5 seconds and centrifuged for 20 140 minutes at 2,500 x g to precipitate the sediment. The supernatant (~80 μL) was pipetted into a 141 glass insert containing 120 μL of 1.9% ammonium hydroxide in 25% aqueous acetonitrile and 142 fitted to an injection vial. The injection volume equaled 12.5 μL. Two mobile phases utilized 143 were as follows: A. 0.1% formic acid in water B. 0.1% formic acid in an acetonitrile at a flow 144 rate of 0.250 mL/min. The mobile phase began at 15% B with a linear gradient to 95% B at 7 145 minutes, which was maintained for 1.5 minutes, followed by a re-equilibration to 15% B. was 99 ± 3% of the actual concentration while the coefficient of variation was 5% determined on 162 4 sets of replicates for each of the following concentrations: 0.015, 0.15, and 1.5 μg/mL. The 163 limit of quantitation (LOQ) for this assay was determined to be 0.005 ug/mL, while the limit of 164 detection (LOD) was 10-fold lower than that at 0.0005 ug/mL. 165 Table 1 summarizes the calculated PK for IV-M and Table 2 summarizes the calculated PK for 204
PO-M. 205
Discussion 206
In this study, we compared the PK parameters of IV and PO meloxicam in mature swine 207 and determined the oral bioavailability. Although meloxicam PK properties were previously 208 evaluated at 0.4 mg/kg in swine (Fosse et al., 2008; 2010), the authors completed this work using 209 younger, immature pigs (14-23 days of age) and did not evaluate PO-M administration. Hence, 210 the present study is novel because we determined these parameters, including oral, in mature pigs 211 using a different route of administration and dose. . Differences in pharmacokinetic parameters from our study compared to previously published 226 results may also be due to differences in age, genetics, weight or additional unknown differences 227 between study populations. Although it is often assumed that young animals always have slower 228 drug metabolism / elimination than adults, this is not the case. In Beagle dogs for example, 229 puppies aged 5-20 weeks have shorter half-lives and more rapid clearance of caffeine than adult 230 dogs (Tanaka et al., 1998) . Similarly the half-life is shorter in puppies aged 3-30 weeks and the 231 clearance is more rapid of trimethadione (a nonspecific metabolism substrate) than adult dogs 232 (Tanaka et al., 1998) . Mosher 
